Major Pharma Scouts Share Their Partnering Tips at RESI JPM

20 Dec

By Lucy Parkinson, VP of Investor Research, LSN

As big pharma companies continue to look outwards for innovative new therapeutics to add to their pipelines, many entrepreneurs are thinking about how to secure a partner even at the earliest stages of product development. At RESI, our Big Pharma panelists will inform the audience on how they source and vet new external opportunities, and what you should be doing to get their support as a partner.

Moderated by Chris Haskell (VP, Head of West Coast Innovation Center – Bayer), the panelists are:

  • Jessica Droge (Executive Director, Business Development – Amgen)
  • Niels Emmerich (Vice President, Global Head Search and Evaluation – AbbVie)
  • Kimberly Folander (Executive Director, Enabling Technologies, BD&L – Merck)
  • Chris Church (Manager, Partnering and Strategy, MedImmune – AstraZeneca)

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future. Join us at RESI to see this panel live.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: